Palvella Therapeutics Submits First Module Of Rolling NDA To FDA Seeking Approval Of QTORIN 3.9% Rapamycin Anhydrous Gel For Treatment Of Mi
Palvella Therapeutics submits first module of rolling NDA to FDA for QTORIN 3.9% rapamycin anhydrous gel approval
S. S. , June 29, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. S.
9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs). Palvella remains on track to submit the remaining modules and complete the NDA submission in the second half of 2026.